Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04769596 · ClinicalTrials.gov registry record · NA
Safety and Efficacy Study of the Neurent Medical NEUROMARK™ System in Subjects With Chronic Rhinitis
A NA study, sponsored by Neurent Medical.
- Completed
- Registry status
- NA
- Development phase
- 143
- Enrollment target
NCT04769596: Completed NA study, sponsored by Neurent Medical.
NCT04769596 is a NA study that has completed, run by Neurent Medical. The registered enrollment target is 143 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04769596, a NA study, has completed, sponsored by Neurent Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 143 participants
- Enrollment target
Study Summary
A randomized, sham-controlled, double-blind study of the NEUROMARKTM system as a treatment for chronic rhinitis
Primary Outcome
Safety
Interventions
- DEVICE Sham Device
- DEVICE NEUROMARK™ System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2021-02-23 |
| Est. Completion | 2023-05-10 |
| Phase | NA |
What the finished NCT04769596 record still lists
NCT04769596 is an interventional study that assigns participants to a tested intervention. The registered 143 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham Device is the first listed.
NCT04769596 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04769596 about?
NCT04769596 is a clinical study titled "Safety and Efficacy Study of the Neurent Medical NEUROMARK™ System in Subjects With Chronic Rhinitis". A randomized, sham-controlled, double-blind study of the NEUROMARKTM system as a treatment for chronic rhinitis
What is the current status of trial NCT04769596?
This trial is currently completed. It is a NA study. The enrollment target is 143 participants. The study started on 2021-02-23. Estimated completion is 2023-05-10.
What interventions are being tested in trial NCT04769596?
The interventions under investigation include: Sham Device (DEVICE), NEUROMARK™ System (DEVICE).
Who is sponsoring clinical trial NCT04769596?
This trial is sponsored by Neurent Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04769596's enrollment target sits among peer trials
143 711th of 2000 higher than 1,290 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI